A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3375880 in Adult Subjects With Moderate-to-Severe Atopic Dermatitis: The ADmIRe Study
Latest Information Update: 12 Dec 2022
At a glance
- Drugs Torudokimab (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Acronyms ADmIRe
- Sponsors Eli Lilly and Company
- 05 Mar 2020 Status changed from active, no longer recruiting to discontinued.
- 18 Feb 2020 Planned End Date changed from 19 Feb 2021 to 28 Feb 2021.
- 18 Feb 2020 Planned primary completion date changed from 14 Feb 2020 to 28 Feb 2020.